News 2025-03-07
Porton Wins Outsourced Pharma 2025 CDMO Leadership Award
In March 2025, Porton Pharma Solutions Ltd. was honored with the "Global Small Molecule API Award" at the 14th Outsourced Pharma CDMO Leadership Awards, recognizing its exceptional end-to-end services across the global small molecule drug lifecycle. This award reaffirms Porton's outstanding performance in the CDMO sector for pharmaceutical R&D and manufacturing worldwide.
The prestigious CDMO Leadership Awards, jointly presented by industry authority Outsourced Pharma and Life Science Connect, celebrates excellence in global biopharmaceutical development and manufacturing services based on global client feedback. Porton's triumph in the "Global Small Molecule API" category demonstrates its extensive capabilities in providing high-quality development and manufacturing solutions for global pharmaceutical companies, innovative drug research institutions, and academic organizations. This recognition emphasizes Porton's support for drug development from preclinical studies through to commercial manufacturing.
"At Porton, we remain committed to customer-centric innovation, providing reliable global solutions to accelerate patients' access to life-changing medicines. We're truly honored by this recognition," said Mr. Oliver Ju, Chairman and CEO of Porton Pharma Solutions. "2025 marks our 20th anniversary, and this achievement confirms our continuous innovation in small molecule API and drug product development, as well as our integrated CDMO service capabilities. We extend our gratitude to global partners for their trust and collaboration!"
About Porton
Founded in 2005, Porton Pharma Solutions Ltd. is an internationally recognized pharmaceutical contract development and manufacturing organization (CDMO) in enabling our global clients to optimize drug development and manufacturing. We provide customer development and manufacturing services for Small Molecules, Tides, Biologics and Conjugates (ADCs, AOCs, PDCs, RDCs, etc.), and Advanced Therapy Medicinal Products from pre-clinical to commercialization stages. As of Dec. 31, 2024, we have a proven record for the delivery of more than 3500 projects and established cooperation with more than 1000 global clients. With our 4200 skilled employees working across 20 sites around the globe, Porton is committed to becoming the most open, innovative and reliable pharmaceutical service platform in the world and enabling the public’s early access to good medicines.
Others
More
News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
